Abstract：In this paper,the treatment of a patient with in-stent thrombosis after percutaneous coronary intervention(PCI)was analyzed in order to provide reference for in-stent thrombosis caused by drugs.The patient developed instent restenosis 1 year after coronary stent implantation.The pharmacist analyzed the patient′s drugs and found that it was related to Clopidogrel resistance.It is suggested that the patients should be examined for gene polymorphism.The results showed that the patient was slow metabolic type.It is suggested that Clopidogrel should be replaced with tigrel,and the platelet aggregation rate can reach the standard after replacement of tigrel,indicating that antiplatelet therapy was effective.Clinical pharmacists provide reference for clinical through the analysis of drugs used by patient.
苏虹；韩瑞兰. 1例经皮冠状动脉介入治疗术后支架内血栓形成患者治疗的病例分析[J]. 中国当代医药, 2021, 28(13): 225-227-241.
SU Hong；HAN Rui-lan. A case analysis of one patient with in-stent thrombosis after percutaneous coronary intervention. 中国当代医药, 2021, 28(13): 225-227-241.
Kishore SP，Blank E，Heller DJ，et al.Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases[J].J Am Coll Cardiol，2018，71（5）：564-574.
Sukiennik A，Kasprzak M，Mazurek W，et al.High-risk percutaneous coronary intervention with impella CP hemodynamic support.A case series and method presentation[J].Postepy Kardiol Interwencyjnej，2017，13（1）：67-71.
[4]
Borovac JA，D′Amario D，Vergallo R，et al.Neoatherosclerosis after drug-eluting stent implantation：a novel clinical and therapeutic challenge[J].Eur Heart J Cardiovasc Pharmacother，2019，5（2）：105-116.
[5]
Stuijfzand WJ，Biesbroek PS，Raijmakers PG，et al.Effects of successful percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function[J].Euro Intervention，2017，13（3）：345-354.
[6]
Mons U，Müezzinler A，Gellert C，et al.Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults：meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium[J].BMJ，2015，350：h1551.
Balakumar P，Kaur J.Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?[J].Pharmacol Res，2009，60（5）：361-368.
[8]
Yagi H，Komukai K，Hashimoto K，et al.Difference in risk factors betweenacute coronary syndrome and stable angina pectoris in the Japanese：Smoking asa crucial risk factor of acute coronary syndrome[J].J Cardiol，2010，55（3）：345-353.
Iakovou I，Schmidt T，Bonizzoni E，et al.Incidence predictors and outcomeof thrombosis after successful implantation of drug-eluting stents[J].JAMA，2005，293（10）：2126-2130.
[11]
Hulot JS，Bura A，Villard E，et al.Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J].Blood，2006，108（7）：2244-2247.
[12]
Mega JL，Close SL，Wiviott SD，et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med，2009，360（4）：354-362.
[13]
Bouman HJ，Schm ig E，van Werkum JW，et al.Paraoxonase-1 is a major determinant of clopidogrel efficacy[J].Nat Med，2011，17（9）：1153.
[14]
Simon T，Verstuyft C，Mary-Krause M，et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med，2009，360（4）：363-375.
Chen Y，Dong W，Wan Z，et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome：a pharmacodynamic analysis[J].Int J Cardiol，2015，201：545-546.
京公网安备 11010502046607号